/VYNE
VYNE Stock - VYNE Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$0.59+0.21%
+$0.00 (+0.21%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.40
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+881.1%upside
Target: $5.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VYNE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.58 – $0.59
TARGET (TP)$5.75
STOP LOSS$0.54
RISK/REWARD1:112.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.00
52W High$4.30
52W Low$0.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $501,000 | $424,000 | $477,000 | $931,000 | $20.99M |
| Gross Profit | $501,000 | $424,000 | $477,000 | $931,000 | $19.60M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 93.4% |
| Operating Income | $-43,637,000 | $-29,258,000 | $-34,295,000 | $-38,911,000 | $252.55M |
| Net Income | $-39,834,000 | $-28,452,000 | $-23,210,000 | $-73,329,000 | $-255,568,000 |
| Net Margin | -7950.9% | -6710.4% | -4865.8% | -7876.4% | -1217.4% |
| EPS | $-0.94 | $-2.77 | $-10.65 | $-25.65 | $-141.90 |
Company Overview
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$8
Average Target
↑ 1265.0% Upside
Now
$8
Low
$8
Average
$8
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 31st 2025 | BTIG Research | Downgrade | Neutral | - |
| November 18th 2024 | BTIG Research | Initiation | Buy | $8 |
Earnings History & Surprises
VYNEBeat Rate
61%
Last 18 quarters
Avg Surprise
+2.5%
EPS vs Estimate
Beats / Misses
11/5
2 met exactly
Latest EPS
$-0.17
Q4 2025
EPS Surprise History
Q1 24
+60.0%
$-0.20vs$-0.50
Q2 24
+37.5%
$-0.15vs$-0.24
Q3 24
-15.8%
$-0.22vs$-0.19
Q4 24
-20.8%
$-0.29vs$-0.24
Q1 25
+9.7%
$-0.28vs$-0.31
Q2 25
+31.0%
$-0.20vs$-0.29
Q3 25
+43.5%
$-0.13vs$-0.23
Q4 25
+10.5%
$-0.17vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.23 | $-0.13 | +43.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.29 | $-0.20 | +31.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.50 | $-0.20 | +60.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.76 | $-1.85 | -143.4% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1.99 | $-3.08 | -54.8% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-2.50 | $-1.74 | +30.4% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-3.24 | $-2.60 | +19.8% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2.88 | $-2.88 | 0.0% | = MET |
Q3 2022 | Aug 12, 2022 | $-2.70 | $-2.34 | +13.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-2.70 | $-2.52 | +6.7% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-4.68 | $-3.60 | +23.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-6.12 | $-6.47 | -5.7% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-6.29 | $-6.29 | 0.0% | = MET |
Latest News
VYNE Therapeutics to merge With Yarrow Bioscience, secures $200M financing; shares up
📈 PositiveSeeking Alpha•Dec 17, 2025, 04:18 PM
VYNE Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement pursuant to combine with Yarrow Bioscience.
📈 PositiveBenzinga•Dec 17, 2025, 01:32 PM
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 17, 2025, 01:25 PM
VYNE Therapeutics Enters All-Stock Merger With Yarrow Bioscience, Combined Co. Will Operate As Yarrow Bioscience
➖ NeutralBenzinga•Dec 17, 2025, 01:03 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 17, 2025, 12:55 PM
VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate
➖ NeutralBenzinga•Nov 6, 2025, 01:29 PM
Frequently Asked Questions about VYNE
What is VYNE's current stock price?
VYNE Therapeutics Inc. (VYNE) is currently trading at $0.59 per share. The stock has moved +0.21% today.
What is the analyst price target for VYNE?
The average analyst price target for VYNE is $5.75, based on 1 analyst.
What sector is VYNE Therapeutics Inc. in?
VYNE Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VYNE's market cap?
VYNE Therapeutics Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does VYNE pay dividends?
No, VYNE Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIM
AIM ImmunoTech Inc.
$1.42
Mkt Cap: $0.0B
BCLI
Brainstorm Cell Therapeutics Inc.
$0.56
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
KALA
KALA BIO, Inc.
$0.62
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
MTNB
Matinas BioPharma Holdings, Inc.
$0.73
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
XTLB
XTL Biopharmaceuticals Ltd.
$0.82
Mkt Cap: $0.0B
Explore stocks similar to VYNE for comparison